Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Opinion on Ibrutinib on 1st Line CLL
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL). Author: obr Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and c
 Rod Humerickhouse discusses the Phase 3 CLL14 Trial. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment with chlorambucil-obinutuzumab ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock MD PhD @charliecraddock of Queen Elizabeth Hospital discusses the Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell ... Author: Annual-Meeting Added: 05/31/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 31, 2019 Category: Cancer & Oncology Source Type: podcasts

Mollie Moran, APRN-CNP, AOCNP - Taking Aim at B-Cell Malignancies With BTK Inhibitors: Oncology Nurse Perspectives and Insights on Clinical Care
Go online to PeerView.com/XAC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to the further integration of BTK inhibitors into treatment plans for patients with cancers such as chronic lymphocytic leukemia (CLL) and mant...
Source: PeerView CME/CE Audio Podcast - Pulmonology - May 27, 2019 Category: Respiratory Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Tanya Siddiqi, MD - Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation
Go online to PeerView.com/ZGE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy (TCT) Meetings in Houston, Texas, experts in hematology and oncology explore the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells and discuss exciting new developments with this innovative approach as well as its clinical potential and role in managing relapsed/refractory hematologic malignancies, including in the context of hematopoietic stem cell transplantation (HCT). The expert panel also shares personal experi...
Source: PeerView CME/CE Audio Podcast - Immunology - April 15, 2019 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways
Earn CME credit for this activity: <a target='_blank' href='https://www.naccme.com/program/2018-802-04'>https://www.naccme.com/prog...</a> This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies in AML, in... Author: imedex Added: 03/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2019 Category: Cancer & Oncology Source Type: podcasts

FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

Molecular Testing & AML
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Molecular Testing & AML. At The 60th ASH Annual Meet... Author: obr Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts

Current Maintenance Regimens For MM
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Current Maintenance Regimens For MM. At The 60th ASH... Author: obr Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts

The POLLUX & CASTOR Clinical Studies
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses The POLLUX & CASTOR Clinical Studies. At The 60th AS... Author: obr Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts

Anti-BCMA CAR-T Cell Therapy In MM
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Anti-BCMA CAR-T Cell Therapy In MM. At The 60th ASH ... Author: obr Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts

How The FLT3 Mutation Influences Treatment Decisions In AML
James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses How The FLT3 Mutation Influences Treatment Decisions In AML. At Th... Author: obr Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts

Using Newly FDA Approved Gilteritinib For Patients With AML
James McClosky, MD Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Using Newly FDA Approved Gilteritinib For Patients With AML. At The ... Author: obr Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts